Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers

Table 3

Summary of original articles from the literature proving the significance of H-FABP as cardiac biomarker.

Authors	Year	Study type	Number of patients	Statistical significance
Sari et al. [1]	2015	Clinical study	67 patients, 40 with diabetes
O’Donoghue et al. [46]	2006	Clinical study	2287 patients with acute coronary syndrome	Elevated in 332 patients (14.5%)
Niizeki et al. [47]	2007	Clinical study	126 patients with chronic heart failure
Willemsen et al. [48]	2015	Clinical study	202 patients with acute coronary syndrome	AUC 0.79 versus 0.80
Viswanathan et al. [49]	2010	Clinical study	1080 patients with suspected acute coronary syndrome
Ruzgar et al. [50]	2006	Clinical study	40 patients with suspected acute coronary syndrome
Mad et al. [51]	2007	Clinical study	22 patients with AMI
			20 with unstable angina and 15 with noncardiac chest pain
Liao et al. [52]	2009	Clinical study	74 patients with AMI
Haltern et al. [53]	2010	Clinical study	97 with acute ischaemic chest pain